type of clinical trial must be aware about the ethical principles that have the origin in the declaration of Helsinki.
To investigate the knowledge of these principles concurring the clinical research among researching physicians and to compare this knowledge among the physicians in different research areas a survey based on 22 questions was send to 1000 hospital physicians in the Copenhagen area (Sovensen, 1997) .
Forty six percent and 304 of these were used for future analysis 821 replied that they had knowledge of good clinical practices nevertheless only 24% were able to recognize the meaning of term "monitor", investigation .and "SOP" when asked about 6 different fictitious situations concerning making reports to an Ethical Review Board (ERB) only 33% replied correctly. This only shows the poor state of awareness about the guidelines of GCP among the researches. A better awareness can not be expected in Indian researches. The guidelines for GCP was developed with consideration of the current GCP of E.Union, Japan and U.S. as well as those of Austria, Canada and nordic countries & WHO.
These guidelines -cover almost all the components of a clinical trial such as patient protection, responsibilities of the sponsors, information management, data processing and quality assurance. Observation of these guidelines and stands must be emphasized chiefly for the reasons of publication suitability and the international recognition of the research and development findings.
THE PRINCIPLES OF GCP
Before any trial is initiated forseeable risks and inconveniences should weight against anticipated benifit of the individual trial subject and society (Oberklaid & Wake, 1997) .
The available information on an investigational products should be adequate to support the proposed trial which is then scientifically described in a detailed protocol which is to be received by IRB/IEC.
Each individual involved in the trial should be qualified and proper informed consent is to be taken from every subject.
All the trial information should be recorded handled and stored in a way that allows its accurate reporting, interpretation and verification. Confidentiality should be maintained, all the investigational products should be manufactured, handled and stored in accordance with good manufacturing practice (GMP).
THE IRB/IEC. (INTERNATIONAL REVIEW BOARD INDEPENDENT ETHICAL COMMITTEE)
The IRB/IEC consists of a group of people with a reasonable number of independent members, who collectively gave qualification and experience to review and evaluate the science, medical aspects and ethics of the proposed clinical trial. Minimum five members are required to form an IRB/IEC. An IRB/IEC should have at least one member whose area of interest is in a non scientific and one member who is independent of the institution /trial site.
There are Certain responsibility of IRB/ IEC. Important ones among them are : 1) It has to obtain all the relevant documents concerning the trial. 2) Safeguards the rights, safety and well being of all the trial subjects.
3) Evaluates the qualification of the investigators. 4) Conducts review of each trial at appropriate interval. 5) Checks the ethical feasibility of any proposed trial and insures that open informed consent is taken from the trial subjects and that the trial conducted in accordance with the protocol and amendments.
IRB/IEC should retain all the relevant records eg. written procedures, membership lists, submitted documents, minutes of meetings and correspondence at least for 3 years after the completion of the trial, and provides them to the investigator, sponsor or regulatory authorities if required.
THE INVESTIGATOR(S)
1) The investigator(s) should be qualified and experienced enough to assure the responsibility for the proper conduct of the trial and should be thoroughly familial with the appropriate one of the investigational products as per the specification provided by the sponsor. The investigator should be aware of and comply with GCP and other regulatory requirements.
2) The investigator should be adequately resourceful to properly conduct the proposed trial that is he should be able to recruit adequate number of trial subjects and staff who help in conducting the trial and it should properly train and inform the staff about the trial related duties and functions.
3) The investigator should ensure that the proper medical care is provided to all the subjects for any adverse events. 4) The investigator must obtain a written approval/option from the IRB/IEC for the trial protocol and it should provide to the IRB/IEC all the appropriate documents for review . 5) The investigator must comply with the protocol agreed upon by the sponsor. Any deviation from the original protocol must be informed to the sponsor & IRB / IEC for the approval . 6) The investigator must ensure that the investigational procedure are used in accordance with the specification provided by sponsor and should ensure that subjects are following instructions properly. 7)The investigator must follow the randomization procedures, follow blinding strictly if required and must break code as per the protocol specification. 8) For any trial either clinical or non clinical which involves human beings as subject a prior consent is a must either from the subjects or legally acceptable representative. This consent which is an informed one is provided both orally as well as a written document contains all the pertinent information about the nature, procedure, associated risks and rights of the subject, is to be duly signed and dated by the subjects or his legally acceptable representative.
Any information which gathered after the trial has started and as relevant should also be provided by the subjects and others associated with the trial. Any change in the protocol should also be informed particularly.
The written informed consent form should address the purpose, procedures, risks & benefit associated with the trial.
The alternative method of treatment should also be informed that the subjects participation is purely voluntary and the provision for the compensation in case of any adverse EDITORIAL: GOOD CLINICAL PRACTICE event & anticipated expanses should also be conveyed. 9) The investigator should ensure the accuracy completeness, legibility & timelines of data gathered from the trial. 10) Written summaries of the trial status should be provided to the IRB / IEC regularly. 11) Any serious adverse event, death should be immediately informed to the sponsor & IRB / IEC. 12) If the trial is terminated prematurily, should ensure appropriate therapy and follow up for subjects. 13) IRB/IEC should ba provided with the summary of the trials out come at the end.
THE SPONSOR
1) The sponsor is responsive fnr implementation and maintenance of the quality assurance and quality control systems to ensure that trial and conducted and data is generated documented and reported as according to the protocol.
2) The sponsor may transfer its trial related duties to a contact research organisation, but the ultimate responsibility lies with the sponsor. 3) May designate qualified medical personnel to advise on related medical problem. 4) The sponsor manages the trial by utilising appropriately qualified individuals for all the aspects of the trial such as appointing an independent data monitoring committee (IDMC) for handling verification of data. All the documents are related to the trial should be at least maintained for 2 years after the discontinuation of the trial. 5) The sponsor selects the qualified investigator/ institution and obtain an agreement from them for proper conductance of the trial according to the protocol & with GCP. 6) Provides insurance to the investigator against claims arising out of the trial and should supervise the compensation paid to the subjects when required. 7) Confirms that the IRB / IEC is organized according to the GCP and has given its approva'l for conducting the trial. 8) Should ensure that all the investigational product are manufactured according to the good manufacturing practice (GMP) properly stored, packaged and coded if required. 9) Ensure that the product are handled & supplied properly in time and are stable over the period of study. 10) The sponsor selects & appoints qualified monitors who verify that the rights of subjects are protected, data generated is accurate & complete and the trial conducted in compliance with the protocol and GCP specification monitor acts as the main line of communication between the sponsor and investigator, it verifies the proper storage and handling of the investigational products. It also informs the investigator of any CRF entry error ommission or illegibility. Prepare the report regularly and submits it to the sponsor.
CLINICAL TRIAL PROTOCOL & AMENDMENTS
The contents of a trial protocol should include the following topics. 1) Should contain all the general information about the identity and addresses of the sponsor, monitor, medical experts, investigator, qualified physician and of labs and departments associated with the trial. 2) Background information about the investigational product and findings from the studies done on the products conducted earlier.Their known benefits and risks and description of the justification of the route of administration dosages, regimen and treatment period. 3) Objectives and purpose of the trial. 4) Description of the trial design.(eg. double blind, single blind, placebo controlled etc.) 5) Subjects inclusions / exclusions criteria ,withdrawl criteria. ,, 6) Treatment schedule of the products, other medication permitted or not permitted, efficacy and safety parameters associated with the trial. 7) Statistics to be employed during and after the trial completion. 8) Details about to be quality assurance, quality control ethical consideration, data handling & record keeping, financing and insurance and publication policies.
In conclusion the scientific community
